

Practice Areas

- Investment Management Group
- Banking and Finance
- Corporate

Education

- J.D., Washington & Lee University School of Law, 1979
- B.A., Princeton University, 1975

Bar Admissions

- New York (1980)
- Virginia (1979)

Lawrence Rimmel

Partner
lremmel@pryorcashman.com

7 Times Square
New York, NY
10036-6569

Direct Tel: 212-326-0881
Direct Fax: 212-798-6365



Lawrence Rimmel specializes in corporate and banking financings, 1940 Act transactions, and asset securitizations, including securitizations involving the biotechnology industry. His work frequently involves intellectual property and licensing issues, in particular in the biotechnology area. Larry has worked on joint ventures, intellectual property transfers and supply and manufacturing agreements. He has been a partner at the firm since 1988.

Larry's representative transactions include:

- Development of Securitized Unregistered Bio-Technology Limited Enhanced™ units, a novel means of securitizing pharmaceutical royalty cash flows
- The Bel Air film financing, providing off-balance sheet studio financing for a renewable slate of films
- Formation of the New Ventures Fund I biotech private equity fund, providing funding to late stage biotechnology companies

Larry provides counsel to Marina Biotech, Inc., various other biotechnology and cosmeceutical companies, and various biotechnology-based private equity funds. In addition, he regularly works with JPMorgan Chase Bank N.A. on Investment Company Act of 1940 transactions, including facilities advised by Deutsche Investment Management Americas. He also lectures from time to time at JPMorgan Chase on the 1940 Act.

Previous Positions

- Reboul, MacMurray, Hewitt, Maynard & Kristol, Associate (1984-88)
- Carter, Ledyard & Milburn, Associate (1979-84)

Speaking Engagements

- Speaker, *Dodd-Frank Financial Reform: Creating a Future of Periodic Failure*, RSM McGladrey, Inc. Risk and Compliance Breakfast (July 2010)
- Panelist, Jefferies Life Sciences Conference on *Structuring Biotech Licenses* (June 2006)

Professional Affiliations

- New York State Bar Association

News

- Pryor Cashman Represents Marina Biotech, Inc. In \$5M Private Placement
- Partner Lawrence Rimmel Interviewed About Barney Frank Retirement
- Partner Lawrence Rimmel Interviewed About Justice Department Banking Probe
- Partner Lawrence Rimmel Interviewed About DOJ Review Of Banks Charging Debit Card Fees
- Partner Lawrence Rimmel Interviewed About The Securitization Of Pharmaceutical Royalty Rights
- Banking Partner Lawrence Rimmel Speaks To TheStreet.Com About Bank of America Mortgage Woes
- Partner Lawrence Rimmel Interviewed About Compliance Duties In Community Banks
- Partner Lawrence Rimmel Interviewed About Recent NCUA Suits Against J.P. Morgan and RBS
- Pryor Cashman Represents Marina Biotech, Inc. in Firm Commitment Underwritten Public Offering
- Partner Lawrence Rimmel Interviewed About Strength Of Corporate Credit Unions
- Partner Lawrence Rimmel Interviewed About Credit Unions and Banks
- Pryor Cashman Represents Marina Biotech, Inc. in Firm Commitment Underwritten Public Offering
- Partner Lawrence Rimmel Quoted In New York Times Story On Wells Fargo
- Pryor Cashman Represents Marina Biotech, Inc. in Registered Direct Offering
- Pryor Cashman Client Marina Biotech, Inc. Acquires SMARTICLES® Intellectual Property
- Pryor Cashman Client Marina Biotech, Inc. Acquires Cequent Pharmaceuticals, Inc.
- Partner Larry Rimmel Speaks To Risk and Compliance Group About Dodd-Frank Financial Reform
- Pryor Cashman client MDRNA, Inc. To Acquire Cequent Pharmaceuticals
- Pryor Cashman Represents MDRNA, Inc. In Registered Direct Offering of Common Stock and Warrants
- Partner Lawrence Rimmel Speaks To US Banker About Emerging Market Woes
- Pryor Cashman Team Closes Biotechnology Financing
- Pryor Cashman Represents JP Morgan Chase Bank, N.A. In Redemption Facility Closing

- Pryor Cashman Is First To Close International Investment Company Redemption Financing
- Pryor Cashman Represented The Purchaser In The Biggest NYC Commercial Property Sale Of 2007
- Pryor Cashman Closes \$1.8 Billion Record-Size Office Building Transaction in Record Time
- Pryor Cashman Assists Biotechnology Investment Company in Formation and Investments
- Pryor Cashman Represents Natestch Pharmaceuticals in Drug Development Deal with Amylin Pharmaceuticals
- Pryor Cashman Team Negotiates Supply Agreement Between Natestch Pharmaceuticals and Procter & Gamble
- Pryor Cashman Represents Natestch Pharmaceutical in Business Expansion Transactions